Clinical outcomes by prospective and retrospective studies
| Hard outcomes | n (N) | Events | OR (95% CI) | p For overall effect | Heterogeneity | Egger's test p value | ||
| Statins | No statins | p Value (Q statistic) | I2 | |||||
| Death from any cause (only prospective studies available) | 2149 (3) | 109/1082 (10.1%) | 109/1067 (10.2%) | 0.98 (0.74 to 1.30) | 0.91 | 0.33 | 9% | 0.15 |
| Death from cardiovascular causes (only prospective studies available) | 2297 (3) | 52/1155 (4.5%) | 64/1142 (5.6%) | 0.79 (0.54 to 1.15) | 0.22 | 0.67 | 0% | 0.70 |
| Aortic valve surgery (only prospective studies available) | 2418 (4) | 311/1216 (25.6%) | 327/1202 (27.2%) | 0.92 (0.76 to 1.10) | 0.35 | 0.43 | 0% | 0.99 |
| Aortic valve stenosis progression | n (N) | Mean difference (95% CI) | p For overall effect | Heterogeneity | Egger's test p value | |
| p Value (Q statistic) | I2 | |||||
| Jet velocity progression (m/s per year) | 3125 (7) | −0.08 (−0.13 to −0.03) | 0.0007 | <0.00001 | 82% | 0.02 |
| Prospective studies | 1948 (3) | −0.05 (−0.13 to 0.03) | 0.22 | 0.01 | 78% | |
| Retrospective studies | 1177 (4) | −0.11 (−0.17 to −0.04) | 0.002 | 0.0002 | 82% | |
| Aortic valve area decrease (sq cm/year) | 2608 (7) | −0.02 (−0.03 to 0.00) | 0.02 | 0.24 | 25% | 0.21 |
| Prospective studies | 2278 (5) | −0.01 (−0.03 to 0.00) | 0.15 | 0.29 | 19% | |
| Retrospective studies | 330 (2) | −0.05 (−0.09 to −0.01) | 0.01 | 1.00 | 0% | |
| Peak aortic gradient progression (mm Hg/year) | 731 (5) | −1.76 (−3.73 to 0.21) | 0.08 | 0.05 | 57% | 0.03 |
| Prospective studies | 524 (3) | −0.67 (−2.89 to 1.54) | 0.55 | 0.15 | 47% | |
| Retrospective studies | 207 (2) | −3.08 (−5.22 to −0.94) | 0.005 | 0.34 | 0% | |
| Mean aortic gradient progression (mm Hg/year) | 2413 (5) | −0.99 (−2.04 to 0.07) | 0.07 | 0.008 | 71% | 0.04 |
| Prospective studies | 2083 (3) | −0.36 (−1.25 to 0.53) | 0.43 | 0.12 | 53% | |
| Retrospective studies | 330 (2) | −1.92 (−3.55 to −0.29) | 0.02 | 0.22 | 35% | |
n, number of patients; N, number of trials.